Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients

Research output: Contribution to journalArticle

Abstract

Natalizumab is a humanized monoclonal antibody against the alpha4 chain of the alpha4beta1 and alpha4beta7 integrin heterodimers used with high effectiveness in the treatment of multiple sclerosis. The use of this drug can unfortunately be associated with the onset of progressive multifocal leukoencephalopathy, a possibly fatal infection of the central nervous system, caused by polyomavirus JC. To understand and quantify the risk of developing PML is important for patients who are about to start therapy with natalizumab and for patients who already are under treatment with this drug. In this review we describe and critique molecular diagnostic tests proposed in the last years to assess the risk of PML.

Original languageEnglish (US)
Pages (from-to)54-62
Number of pages9
JournalMolecular and Cellular Probes
Volume29
Issue number1
DOIs
StatePublished - Feb 1 2015

Fingerprint

Progressive Multifocal Leukoencephalopathy
Molecular Pathology
Routine Diagnostic Tests
Multiple Sclerosis
JC Virus
Integrin alpha4beta1
Antibodies, Monoclonal, Humanized
Central Nervous System Infections
Pharmaceutical Preparations
Therapeutics
Natalizumab

Keywords

  • JCV
  • Multiple sclerosis
  • Natalizumab
  • PML

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

@article{b603d74cdf78479b808acf5a9896948d,
title = "Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients",
abstract = "Natalizumab is a humanized monoclonal antibody against the alpha4 chain of the alpha4beta1 and alpha4beta7 integrin heterodimers used with high effectiveness in the treatment of multiple sclerosis. The use of this drug can unfortunately be associated with the onset of progressive multifocal leukoencephalopathy, a possibly fatal infection of the central nervous system, caused by polyomavirus JC. To understand and quantify the risk of developing PML is important for patients who are about to start therapy with natalizumab and for patients who already are under treatment with this drug. In this review we describe and critique molecular diagnostic tests proposed in the last years to assess the risk of PML.",
keywords = "JCV, Multiple sclerosis, Natalizumab, PML",
author = "Francesca Rossi and Scott Newsome and Viscidi, {Raphael P}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.mcp.2014.11.007",
language = "English (US)",
volume = "29",
pages = "54--62",
journal = "Molecular and Cellular Probes",
issn = "0890-8508",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients

AU - Rossi, Francesca

AU - Newsome, Scott

AU - Viscidi, Raphael P

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Natalizumab is a humanized monoclonal antibody against the alpha4 chain of the alpha4beta1 and alpha4beta7 integrin heterodimers used with high effectiveness in the treatment of multiple sclerosis. The use of this drug can unfortunately be associated with the onset of progressive multifocal leukoencephalopathy, a possibly fatal infection of the central nervous system, caused by polyomavirus JC. To understand and quantify the risk of developing PML is important for patients who are about to start therapy with natalizumab and for patients who already are under treatment with this drug. In this review we describe and critique molecular diagnostic tests proposed in the last years to assess the risk of PML.

AB - Natalizumab is a humanized monoclonal antibody against the alpha4 chain of the alpha4beta1 and alpha4beta7 integrin heterodimers used with high effectiveness in the treatment of multiple sclerosis. The use of this drug can unfortunately be associated with the onset of progressive multifocal leukoencephalopathy, a possibly fatal infection of the central nervous system, caused by polyomavirus JC. To understand and quantify the risk of developing PML is important for patients who are about to start therapy with natalizumab and for patients who already are under treatment with this drug. In this review we describe and critique molecular diagnostic tests proposed in the last years to assess the risk of PML.

KW - JCV

KW - Multiple sclerosis

KW - Natalizumab

KW - PML

UR - http://www.scopus.com/inward/record.url?scp=84923574203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923574203&partnerID=8YFLogxK

U2 - 10.1016/j.mcp.2014.11.007

DO - 10.1016/j.mcp.2014.11.007

M3 - Article

C2 - 25483260

AN - SCOPUS:84923574203

VL - 29

SP - 54

EP - 62

JO - Molecular and Cellular Probes

JF - Molecular and Cellular Probes

SN - 0890-8508

IS - 1

ER -